32
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

      ,
      Nature Reviews Cardiology
      Springer Science and Business Media LLC

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references124

          • Record: found
          • Abstract: found
          • Article: not found

          Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

          The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

            Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

              Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycaemic control.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                (View ORCID Profile)
                Journal
                Nature Reviews Cardiology
                Nat Rev Cardiol
                Springer Science and Business Media LLC
                1759-5002
                1759-5010
                March 28 2023
                Article
                10.1038/s41569-023-00849-3
                36977782
                88807607-73fb-416b-b8e7-c63ab9ad8235
                © 2023

                https://www.springernature.com/gp/researchers/text-and-data-mining

                https://www.springernature.com/gp/researchers/text-and-data-mining

                History

                Comments

                Comment on this article